Patents by Inventor Manuel Baca

Manuel Baca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD40L-specific TN3-derived scaffolds and methods of use thereof
    Patent number: 10000553
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 19, 2018
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1
    Publication number: 20170369579
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Application
    Filed: September 6, 2017
    Publication date: December 28, 2017
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • ANTI-VEGF ANTIBODIES
    Publication number: 20170369564
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • CD40L-Fc Fusion Polypeptides And Methods Of Use Thereof
    Publication number: 20170327588
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Application
    Filed: May 12, 2017
    Publication date: November 16, 2017
    Inventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 9777062
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 3, 2017
    Assignee: CSL Limited
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20170226214
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 10, 2017
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1
    Publication number: 20160362497
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Application
    Filed: May 20, 2016
    Publication date: December 15, 2016
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • ANTI-VEGF ANTIBODIES
    Publication number: 20160257738
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: October 6, 2015
    Publication date: September 8, 2016
    Applicant: GENENTECH, INC.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 9371388
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: June 21, 2016
    Assignee: CSL Limited
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20160031998
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • TRAIL R2-specific multimeric scaffolds
    Patent number: 9212231
    Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: December 15, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
  • Antibodies against G-CSFR and uses thereof
    Patent number: 9193793
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 24, 2015
    Assignee: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • Protein scaffolds
    Patent number: 9176129
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 3, 2015
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko
  • CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS AND METHODS OF USE THEREOF
    Publication number: 20150098955
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: October 10, 2012
    Publication date: April 9, 2015
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • ANTI-VEGF ANTIBODIES
    Publication number: 20150023951
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: February 3, 2014
    Publication date: January 22, 2015
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • METHOD OF TREATING CANCER COMPRISING A VEGF-B ANTAGONIST
    Publication number: 20140363445
    Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
    Type: Application
    Filed: August 11, 2014
    Publication date: December 11, 2014
    Applicant: ZENYTH OPERATIONS PTY LTD
    Inventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
  • Method of treating cancer comprising a VEGF-B antagonist
    Patent number: 8822644
    Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: September 2, 2014
    Assignee: Zenyth Operations Pty Ltd
    Inventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
  • Protein Scaffolds
    Publication number: 20140141994
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Application
    Filed: December 13, 2013
    Publication date: May 22, 2014
    Applicant: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko
  • HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1
    Publication number: 20140056915
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Application
    Filed: October 14, 2013
    Publication date: February 27, 2014
    Applicant: CSL Limited
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • Protein scaffolds
    Patent number: 8633297
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: January 21, 2014
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko